Enhancing Pancreatic Cancer Therapy With Targeted CD133-Exosome Delivery of PD-L1 siRNA
PD-L1 siRNA-loaded CD133-tEx demonstrated remarkable anticancer efficacy, characterized by specific binding to CD133-positive pancreatic cancer cells and suppression of PD-L1 expression within these cells.
Authors
- Young Chul Yoon (ORCID: https://orcid.org/0000-0002-5341-2370)
- Say‐June Kim (ORCID: https://orcid.org/0000-0001-5171-4837)
- Dosang Lee (ORCID: https://orcid.org/0000-0002-1528-2317)
- Ho Joong Choi (ORCID: https://orcid.org/0000-0002-0862-098X)
- Ok‐Hee Kim (ORCID: https://orcid.org/0000-0002-9204-2587)
- Jung Hyun Park
Institutions
- Korea Pharma (South Korea) (KR)
- The Catholic University of Korea Incheon St. Mary's Hospital (KR)
- The Catholic University of Korea Seoul St. Mary's Hospital (KR)
- Catholic University of Korea (KR)
Publication Details
- Journal
- Pancreas
- Published
- 2024-11-26
- DOI
- https://doi.org/10.1097/mpa.0000000000002419
- Citations
- 3
- Primary Topic
- Extracellular vesicles in disease
- Type
- article
- Field-Weighted Citation Impact
- 0.70